Petlife Pharmaceuticals, Inc. (PTLF)

Market Cap	22.43K +1.0%
Revenue (ttm)	n/a
Net Income	-3.71M
EPS	-0.04
Shares Out	222.12M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,000
Open	0.0001
Previous Close	n/a
Day's Range	0.0001 - 0.0001
52-Week Range	0.0001 - 0.0002
Beta	63.75
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Petlife Pharmaceuticals

Petlife Pharmaceuticals, Inc. engages in the research, development, sale, and support of drugs and nutraceuticals for pet cancer and autoimmune related diseases, such as arthritis in the United States. The company’s principal product is Vitalzul that inhibits blood vessels formation in solid tumors. It is also developing Vitalzul as a prescription strength oral pharmaceutical, as well as a concentrated intravenous and injectable version for direct administration to a tumor. In addition, the company develops edible dog and cat treats. Petlife Ph...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• CEO: Sebastian Serrell-Watts
• Employees: 1
• Stock Exchange: OTCMKTS
• Ticker Symbol: PTLF

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 30, 2026

Data Sources Report a data error